Early Access — free while we kick the tires
EdgarHawk

STAHL NEIL

EVP Research and Development

Officer
1 filing analyzed · 1 company · Latest 2024-08-12

Companies

Company Buys Sells Direction
REGENERON PHARMACEUTICALS, INC. REGN 0 7 Net selling

Activity

August 2024
Sell
5,197 shares
$5,636,346
Significance 4/10

EVP Stahl sold 5,197 shares at $1,084.54 blended avg for $5.6M; retains 50.1K shares post-sale.

Neil Stahl, EVP Research and Development at Regeneron, executed 6 separate sales totaling 5,197 shares for $5,636,346.27 on 2024-08-08, reducing his holdings from 55.3K to 50.1K shares (-9.4%). The stock has since appreciated to $1121.09, trading near its 52-week high of $1131.24, and has gained 13.9% over the trailing 90 days. Notably, Stahl's prior 5 open-market sales at REGN (all on 2024-02-07) posted subsequent 30-day and 90-day gains ranging from +1.7% to +2.4%, with a 0% well-timed rate at the 90-day mark—meaning the stock rose materially after each prior sale. His cross-ticker track record shows only a 30% well-timed sell rate across 10 prior dispositions. The current sale occurred near the stock's 52-week high, though the insider retains a substantial 50.1K-share position, reflecting continued meaningful ownership in the $105.3B market-cap enterprise.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access